Lantern Pharma (LTRN) Tops Q4 EPS by 16c
Tweet
Share
E-mailGet Alerts LTRN Hot Sheet
Join SI Premium – FREE
Lantern Pharma (NASDAQ: LTRN) reported Q4 EPS of ($0.31), $0.16 better than the analyst estimate of ($0.47).
For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AngioDynamics (ANGO) Tops Q4 EPS by 2c ; Offers Guidance
- AngioDynamics reports fiscal 2026 full-year net sales of $320M
- Barclays on Rivian (RIVN) into earnings: 'Autonomy remains show me'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
